What neurotransmitters are primarily affected by Bupropion?

Bupropion primarily affects the neurotransmitters norepinephrine and dopamine. It acts as a norepinephrine-dopamine reuptake inhibitor (NDRI), which means it enhances the levels of these neurotransmitters in the synaptic cleft by inhibiting their reabsorption into the presynaptic neuron. This mechanism of action is particularly relevant in the treatment of major depressive disorder and is also utilized for smoking cessation. The increase in norepinephrine is associated with improvements in mood and energy levels, while the elevation of dopamine is linked to enhanced motivation and pleasure.

Other neurotransmitters listed in the choices, such as serotonin, acetylcholine, histamine, GABA, and norepinephrine, do not play a primary role in the action of bupropion. For instance, although some antidepressants primarily target serotonin, such as selective serotonin reuptake inhibitors (SSRIs), bupropion focuses on norepinephrine and dopamine regulation. Understanding the specific neurotransmitter interactions is crucial for tailoring pharmacological treatments for various psychiatric disorders.